BAY 43-9006
BAY 43-9006 is a pharmaceutical drug with 9 clinical trials. Historical success rate of 88.9%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
88.9%
8 of 9 finished
11.1%
1 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Clinical Trials (9)
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9